Article (Scientific journals)
Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation.
Schetelig, Johannes; Fetscher, Sebastian; Reichle, Albrecht et al.
2003In Haematologica, 88 (11), p. 1272-8
Peer Reviewed verified by ORBi
 

Files


Full Text
193.pdf
Publisher postprint (114.54 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Adult; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Health Surveys; Humans; Immunoblastic Lymphadenopathy/drug therapy/mortality/therapy; Life Tables; Lymphoma, T-Cell/drug therapy/mortality/therapy; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome
Abstract :
[en] BACKGROUND AND OBJECTIVES: Patients with angioimmunoblastic T-cell lymphoma (AIL) have a poor prognosis with conventional treatment. DESIGN AND METHODS: We initiated an EBMT-based survey studying the impact of high-dose chemotherapy (HDCT) and autologous hematopoietic stem cell transplantation in patients with AIL. Data on 29 patients, who were transplanted between 1992 and 1998 in 16 transplant centers, were collected on standardized documentation forms. RESULTS: The median age at transplantation was 53 years. HDCT was given as part of 1st-line therapy (N=14; 48%) or 2nd/3rd-line therapy (N=15; 52%). Regimens for the mobilization of peripheral blood stem cells (PBSC) included VIPE (N=7; 26%), DexaBEAM (N=6; 22%), CHOP-like regimens (N=6; 22%), other regimens (N=5; 19%) or alternatively growth factor alone (N=3; 11%). The median yield of PBSC was 3.8x106 CD34+cells/kg. Two patients received autologous bone marrow. The HDCT consisted of BEAM-type regimens in 16 patients, ICE-type regimens in 7, and other regimens in 6 patients. There was one treatment-related death. The rate of complete remissions increased from 45% before HDCT to 76% after HDCT. As of January 2003, after a median observation time of living patients of 5 years (range 2.5 to 10 years), 14 patients have died (13 from progressive disease), and 15 patients are alive. The probability of 5-year overall and event-free survival was 44% (95% CI, 22% to 66%) and 37% (95% CI, 17% to 57%), respectively. Long-term disease-free survival was observed in patients transplanted during 1st-line treatment as well as in the context of 2nd/3rd-line therapy. INTERPRETATION AND CONCLUSIONS: There is evidence that AIL is susceptible to high-dose chemotherapy. HDCT and autologous stem cell transplantation should be considered in selected patients with AIL.
Disciplines :
Hematology
Author, co-author :
Schetelig, Johannes
Fetscher, Sebastian
Reichle, Albrecht
Berdel, Wolfgang E
Beguin, Yves  ;  Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Brunet, Salut
Caballero, Dolores
Majolino, Ignazio
Hagberg, Hans
Johnsen, Hans E
Kimby, Eva
Montserrat, Emilio
Stewart, Douglas
Copplestone, Adrian
Rosler, Wolf
Pavel, Jindra
Kingreen, Dorothea
Siegert, Wolfgang
More authors (8 more) Less
Language :
English
Title :
Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation.
Publication date :
2003
Journal title :
Haematologica
ISSN :
0390-6078
eISSN :
1592-8721
Publisher :
Ferrata Storti Foundation, Pavia, Italy
Volume :
88
Issue :
11
Pages :
1272-8
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 16 March 2009

Statistics


Number of views
244 (0 by ULiège)
Number of downloads
538 (0 by ULiège)

Scopus citations®
 
82
Scopus citations®
without self-citations
78

Bibliography


Similar publications



Contact ORBi